1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Interview: Atox Aims For Reltecimod OK In 2020

 
• By Kevin Grogan

The Israeli biotech is eagerly awaiting Phase III data on its therapy for necrotizing soft tissue infections before the end of 2019.

Timer
Waiting time nearly over for reltecimod data • Source: Shutterstock

Atox Bio Inc. could soon have a marketed product on its hands as the Israeli biotech gets ready for late-stage data readouts on its flesh-eating bacteria immune modulator reltecimod and a US filing next year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.